Ashwagandha is marketed as a cognitive enhancer, but the evidence tells a more precise story — it’s a stress and cortisol adaptogen first, with cognitive benefits that appear downstream of reduced stress rather than as a direct effect.
Ashwagandha KSM-66 has a more rigorous clinical evidence base than almost anyone in the nootropic community appreciates — including a trial showing 27.9% cortisol reduction with direct serum measurement and across-the-board cognitive improvements in healthy adults at 8 weeks. After 18+ years of research, here is the complete evidence-based guide to the stress substrate compound that determines how well everything else in the protocol performs.
